HIMS stock sentiment todayHims & Hers Health, Inc.

A high-growth disruptor bridging the gap between telehealth and compounding pharmacy, currently riding a massive GLP-1 and regulatory tailwind.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for HIMS. Not financial advice.

The narrative is dominated by regulatory wins and geographic expansion. Recent HHS/FDA clarifications on peptide compounding have removed a significant 'cloud of uncertainty' regarding their weight-loss business, while international launches in Australia and Germany signal a pivot to a global lifestyle brand rather than just a domestic pill-mill.

• ·FDA/HHS temporary clearance of peptide compounding
• ·Speculation on RFK Jr.'s potential impact on FDA regulatory hurdles
• ·Global expansion (Australia/Germany) reducing geographic concentration risk
• ·Sympathy moves with Teladoc suggesting a rising tide for the telehealth sector

HIMS has achieved the rare 'Rule of 40' status in SaaS/Health-tech, combining hyper-growth (50%+) with GAAP profitability. Their shift toward personalized, multi-condition subscriptions is driving high recurring revenue and industry-leading gross margins near 80%.

• ·Revenue growth exceeding 50% YoY
• ·Gross margins consistently ~80%
• ·Positive and accelerating Net Income/EBITDA
• ·Zero long-term debt with a strong cash position

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Strong conviction — insiders and patient capital are backing this.

• ·No open-market insider trades in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Regulatory reversal on compounded GLP-1s if drug shortages end
• ·Heavy marketing spend required to maintain low churn
• ·Intense pricing competition from Amazon Clinic and Ro

How direct competitors stack up against HIMS right now.

• COLD
  TDOCTeladoc Health

  COLDER — despite recent earnings beats, it lacks HIMS's high-margin proprietary product vertical and suffers from stagnant growth and massive historical impairments.

  See full analysis →
• NEUTRAL
  AMZNAmazon (Amazon Clinic)

  NEUTRAL — while possessing infinite scale, their healthcare offerings lack the 'lifestyle brand' loyalty and specific compounding focus that HIMS utilizes to capture high-intent Gen Z/Millennial spend.

  See full analysis →
• NEUTRAL
  RDYDr. Reddy's Laboratories

  COLDER — trades at a much lower P/E as a traditional generic drug manufacturer, but lacks the direct-to-consumer digital platform and recurring subscription tailwinds driving HIMS's valuation.

  See full analysis →

Consensus average of 11 analysts · median 32.00

Source: StockAnalysis.com · updated 2026-10-29

• Yahoo Finance
  Hims And Hers Health (HIMS) Stock May Trade At A Discount Despite Australia Launch
• Investor's Business Daily
  RFK Jr. Pulls An End-Around On The FDA; Why Hims Surged
• Seeking Alpha
  Hims & Hers rises as U.S. to allow compounding of six peptides
• 24/7 Wall St.
  Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
• Trefis
  What Are Hims & Hers Health Stock Investors Overlooking?
• Yahoo Finance
  Hims & Hers Health, Inc. (HIMS) Stock Forecasts